Association of Proton Pump Inhibitors With Hospitalization Risk in Children With Oropharyngeal Dysphagia

Abstract

IMPORTANCE Proton pump inhibitors (PPI) are commonly prescribed to children with oropharyngeal dysphagia and resultant aspiration based on the assumption that these patients are at greater risk for reflux-related lung disease. There is little data to support this approach and the potential risk for increased infections in children treated with PPI may outweigh any potential benefit. OBJECTIVE The aim of this study was to determine if there is an association between hospitalization risk in pediatric patients with oropharyngeal dysphagia and treatment with PPI. DESIGN, SETTING, AND PARTICIPANTS We performed a retrospective cohort study to compare the frequency and length of hospitalizations for children who had abnormal results on videofluoroscopic swallow studies that were performed between January 1, 2015, and December 31, 2015, and who were or were not treated with PPI, with follow-up through December 31, 2016. Records were reviewed for children who presented for care at Boston Children's Hospital, a tertiary referral center. Participants included 293 children 2 years and younger with evidence of aspiration or penetration on videofluoroscopic swallow study. EXPOSURES Groups were compared based on their exposure to PPI treatment. MAIN OUTCOMES AND MEASURES The primary outcomes were hospital admission rate and hospital admission nights and these were measured as incident rates. Multivariable analyses were performed to determine predictors of hospitalization risk after adjusting for comorbidities. Kaplan-Meier curves were created to determine the association of PPI prescribing with time until first hospitalization. RESULTS A total of 293 patients with a mean (SD) age of 8.8 (0.4) months and a mean (SD) follow-up time of 18.15 (0.20) months were included in the analysis. Patients treated with PPI had higher admission rates (Incidence rate ratio [IRR], 1.77; 95% CI, 1.16-2.68) and admission nights (IRR, 2.51; 95% CI, 1.36-4.62) even after adjustment for comorbidities. Patients with enteral tubes who were prescribed PPIs were at the highest risk for admission (hazard ratio [HR], 2.31; 95% CI, 1.24-4.31). CONCLUSIONS AND RELEVANCE Children with aspiration who are treated with PPI have increased risk of hospitalization compared with untreated patients. These results support growing concern about the risks of PPI use in children.

Comparison of common interventions for the treatment of infantile colic: a systematic review of reviews and guidelines

“…We are aware, however, of the practice of using PPIs to diagnose GORD by treatment 44. PPIs are designed to suppress acid but have consistently been shown to be ineffective for irritability and fussing in infants with GORD, and they are associated with an increased risk of adverse effects such as infections, allergies and hospital admissions 9 21 35 45 46. There is evidence from Australia to show that PPIs are being over-prescribed for infants with physiological reflux and symptoms of colic who may or do not have GORD.…”

Gastro-oesophageal reflux disease in children with neurological impairment: a retrospective cohort study

“…A retrospective cohort study in paediatrics showed a nearly twofold increase in hospitalisations for children with dysphagia who were treated with a PPI compared with untreated children. 47 A large population-based cohort study demonstrated a twofold increased risk of community-acquired pneumonia in children treated with PPIs compared with controls with an even greater risk in children with disability. 5 Further, children with NI have increased baseline risk of low bone mineral density and fractures as well as alterations in gut flora if they are enterally fed.…”

Predictive Utility of the Penetration‐Aspiration Scale in Inter‐Arytenoid Injection Augmentation

“…An explanation for this could be that the decision to prescribe AST for specific patients was left to individual providers. There is also variation even within each provider's cohort over time as data have emerged showing potential for significant complications with use of AST 18, 19 . These cohorts of patients should be further investigated to determine whether PAS score may be a useful predictor of which patients will benefit from AST and which will not.…”